CRIS Current Research Information System

PALLADINI, ARIANNA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 4.010
AS - Asia 3.524
EU - Europa 2.516
AF - Africa 224
Continente sconosciuto - Info sul continente non disponibili 224
SA - Sud America 160
OC - Oceania 7
Totale 10.665
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.920
VN - Vietnam 1.195
CN - Cina 886
SG - Singapore 771
IT - Italia 740
GB - Regno Unito 468
DE - Germania 288
HK - Hong Kong 209
SE - Svezia 200
FR - Francia 134
IN - India 122
RU - Federazione Russa 116
BR - Brasile 115
NL - Olanda 101
UA - Ucraina 89
CH - Svizzera 78
IE - Irlanda 77
BD - Bangladesh 73
CI - Costa d'Avorio 72
ZA - Sudafrica 61
CA - Canada 60
JP - Giappone 59
KR - Corea 51
FI - Finlandia 48
TG - Togo 45
EE - Estonia 35
BG - Bulgaria 32
BE - Belgio 27
PH - Filippine 22
ID - Indonesia 20
TH - Thailandia 19
AR - Argentina 18
LT - Lituania 14
MX - Messico 14
JO - Giordania 13
RO - Romania 13
AT - Austria 12
IQ - Iraq 12
PL - Polonia 12
SC - Seychelles 12
TW - Taiwan 12
EG - Egitto 11
TR - Turchia 10
EC - Ecuador 9
PK - Pakistan 9
CL - Cile 7
CO - Colombia 7
SA - Arabia Saudita 7
AU - Australia 6
HR - Croazia 6
NG - Nigeria 6
DK - Danimarca 5
IR - Iran 5
JM - Giamaica 5
MA - Marocco 5
AE - Emirati Arabi Uniti 4
ES - Italia 4
GR - Grecia 4
DO - Repubblica Dominicana 3
HN - Honduras 3
LB - Libano 3
UZ - Uzbekistan 3
AZ - Azerbaigian 2
BY - Bielorussia 2
CR - Costa Rica 2
CZ - Repubblica Ceca 2
GH - Ghana 2
KE - Kenya 2
KG - Kirghizistan 2
KH - Cambogia 2
KZ - Kazakistan 2
LI - Liechtenstein 2
MN - Mongolia 2
MY - Malesia 2
PS - Palestinian Territory 2
TN - Tunisia 2
VE - Venezuela 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AL - Albania 1
AM - Armenia 1
AO - Angola 1
BB - Barbados 1
BJ - Benin 1
BO - Bolivia 1
DM - Dominica 1
DZ - Algeria 1
ET - Etiopia 1
GE - Georgia 1
HU - Ungheria 1
IL - Israele 1
LA - Repubblica Popolare Democratica del Laos 1
LV - Lettonia 1
MD - Moldavia 1
NI - Nicaragua 1
NZ - Nuova Zelanda 1
PE - Perù 1
PT - Portogallo 1
QA - Qatar 1
RS - Serbia 1
SI - Slovenia 1
Totale 10.440
Salva come PNG Salva come JPEG
Città #
Singapore 543
Ashburn 449
Fairfield 392
Southend 370
Chandler 328
Ho Chi Minh City 272
Hanoi 233
Hong Kong 201
Houston 180
San Jose 180
Shanghai 175
Woodbridge 172
Wilmington 170
Bologna 163
Ann Arbor 158
Seattle 146
Dong Ket 132
Cambridge 130
Council Bluffs 125
Santa Clara 120
Beijing 103
Hefei 103
Princeton 93
Dublin 76
Boardman 74
Abidjan 72
Bern 70
New York 60
Los Angeles 59
Jacksonville 53
Lauterbourg 52
Milan 48
Lomé 45
Dallas 44
Tokyo 44
Seoul 39
Westminster 39
Bremen 37
Nanjing 37
Helsinki 36
Da Nang 35
Haiphong 35
Padova 33
Berlin 32
Sofia 32
Guangzhou 31
Buffalo 28
Jinan 28
Redmond 26
Brussels 25
Frankfurt am Main 25
Redwood City 24
São Paulo 23
Redondo Beach 21
Saint Petersburg 21
Casalecchio di Reno 20
Johannesburg 20
London 20
Tianjin 20
Turin 20
Falkenstein 19
Ottawa 19
Amsterdam 18
Hải Dương 18
San Diego 18
Toronto 18
Changsha 17
Jakarta 17
Phoenix 17
Shenyang 15
Hebei 14
Amman 13
Biên Hòa 13
Des Moines 13
Atlanta 12
Jiaxing 12
Nanchang 12
Ha Long 11
Zhengzhou 11
Bengaluru 10
Moscow 10
Mülheim 10
Lappeenranta 9
Montreal 9
Quận Bình Thạnh 9
Vienna 9
Bến Tre 8
Can Tho 8
Delhi 8
Naples 8
Vicenza 8
Barnet 7
Bühl 7
Bắc Giang 7
Chicago 7
Chieti 7
Crocetta 7
Kerpen 7
Ningbo 7
Orem 7
Totale 6.798
Salva come PNG Salva come JPEG
Nome #
IFN-γ and CD38 in Hyperprogressive Cancer Development 442
Vaccines against human HER2 prevent mammary carcinoma in mice transgenic for human HER-2. 387
Early stability and late random tumor progression of a HER2-positive primary breast cancer patient-derived xenograft 345
Bone sarcoma patient-derived xenografts are faithful and stable preclinical models for molecular and therapeutic investigations 326
A multi-DNA preventive vaccine for p53/Neu driven cancer syndrome 269
Systemic delivery of HER2-retargeted oncolytic-HSV by mesenchymal stromal cells protects from lung and brain metastases 263
Preclinical therapy of disseminated HER-2+ ovarian and breast carcinomas with a HER-2-retargeted oncolytic herpesvirus. 260
Cancer Vaccines Co-Targeting HER2/Neu and IGF1R 248
Virus-like particle display of HER2 induces potent anti-cancer responses 233
Multiorgan Metastasis of Human HER-2+ Breast Cancer in Rag2−/−;Il2rg−/− Mice and Treatment with PI3K Inhibitor 233
Evolution of HER2-positive mammary carcinoma: HER2 loss reveals claudin-low traits in cancer progression 224
Targeting PCSK9, through an innovative cVLP-based vaccine, enhanced the therapeutic activity of a cVLP-HER2 vaccine in a preclinical model of HER2-positive mammary carcinoma 221
Tamoxifen combined to anti-HER-2/neu cell vaccine does not hamper cancer immunopreventive efficacy 220
ADK-VR2, a cell line derived from a treatment-naïve patient with SDC4-ROS1 fusion-positive primarily crizotinib-resistant NSCLC: a novel preclinical model for new drug development of ROS1- rearranged NSCLC 216
Bioprofiling TS/A Murine Mammary Cancer for a Functional Precision Experimental Model 210
Cancer immunoprevention: from mice to early clinical trials 209
Endothelin-3 production by human rhabdomyosarcoma: A possible new marker with a paracrine role. 204
Pathobiological implications of the d16HER2 splice variant for stemness and aggressiveness of HER2-positive breast cancer 204
Lipid rafts, caveolae, and epidermal growth factor receptor family: friends or foes? 203
HER-2/neu tolerant and non-tolerant mice for fine assessment of antimetastatic potency of dendritic cell-tumor cell hybrid vaccines 202
In silico modeling and in vivo efficacy of cancer preventive vaccinations 202
Genomic Landscape, Clinical Features and Outcomes of Non-Small Cell Lung Cancer Patients Harboring BRAF Alterations of Distinct Functional Classes 200
Evaluation of metastatic burden and recovery of human metastatic cells from a mouse model 200
ImmunoGrid: Towards agent-based simulations of the human immune system at a natural scale 199
The mechanisms of PD-L1 regulation in non-small-cell lung cancer (NSCLC): Which are the involved players? 196
Immune targeting of autocrine IGF2 hampers rhabdomyosarcoma growth and metastasis 190
Gene expression analysis of immune-mediated arrest of tumorigenesis in a transgenic mouse model of HER-2/neu-positive basal-like mammary carcinoma. 189
Tumor suppressor genes promote rhabdomyosarcoma progression in p53 heterozygous, HER-2/neu transgenic mice. 189
High metastatic efficiency of human sarcoma cells in Rag2/gamma c double knockout mice provides a powerful test system for antimetastatic targeted therapy 189
Antimetastatic activity of a preventive cancer vaccine. 188
Interleukin-15 is required for immunosurveillance and immunoprevention of HER2/neu-driven mammary carcinogenesis 187
Human responses against HER-2-positive cancer cells in human immune system-engrafted mice. 187
Prevention and Therapy of Metastatic HER-2+ Mammary Carcinoma with a Human Candidate HER-2 Virus-like Particle Vaccine 183
HER2 isoforms co-expression differently tunes mammary tumor phenotypes affecting onset, vasculature and therapeutic response 182
Expression of a functional CCR7 chemokine receptor inhibits the post-intravasation steps of metastasis in malignant murine mammary cancer cells 179
Opposing control of rhabdomyosarcoma growth and differentiation by myogenin and interleukin 4. 179
Modeling the competition between lung metastases and the immune system using agents. 178
Genetic prevention of lymphoma in p53 knockout mice allows the early development of p53-related sarcomas 177
OX40 triggering concomitant to IL12-engineered cell vaccine hampers the immunoprevention of HER2/neu-driven mammary carcinogenesis 177
Translational immunomics of cancer prevention. 169
Activated d16HER2 Homodimers and SRC Kinase Mediate Optimal Efficacy for Trastuzumab. 169
Immune checkpoint inhibitors in lung tumors with rare histologies and other thoracic malignancies 166
Expression of connective tissue growth factor (CTGF/CCN2) in a mouse model of rhabdomyosarcomagenesis. 163
Inhibition of prostate carcinogenesis by combined active immunoprophylaxis. 162
HER Tyrosine Kinase Family and Rhabdomyosarcoma: Role in Onset and Targeted Therapy 162
Proteomic and PROTEOMEX profiling of mammary cancer progression in a HER-2/neu oncogene-driven animal model system 150
Computational models as novel tools for cancer vaccines. 143
ImmunoGrid, an integrative environment for large-scale simulation of the immune system for vaccine discovery, design, and optimization 131
Mathematical and computational models in tumor immunology 130
EGFR-RAD51 gene fusion NSCLC responsiveness to different generation EGFR-TKIs: two cases and review of the literature 107
Predictive models in tumor immunology. 92
Development of cellular models expressing cynomolgus (Macaca fascicularis) HER2 for the functional evaluation of cross-reactive anti-human HER2 response 86
Targeting HGF/MET and CXCL1/CXCR2 axes bypasses resistance to KRASG12C inhibitors in NSCLC 66
Requalified bovine milk as a sustainable supplement for cell cultures 40
Alternatives for fetal bovine serum (FBS) and sustainability of milk derivatives in cell culture 39
Totale 10.665
Salva come PNG Salva come JPEG
Categoria #
all - tutte 28.401
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 28.401
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022903 0 47 83 38 99 70 29 54 52 66 223 142
2022/20231.261 132 154 67 183 75 99 44 66 180 54 103 104
2023/2024490 25 45 22 32 29 50 25 209 7 19 11 16
2024/20251.409 102 166 112 75 230 78 101 68 9 115 82 271
2025/20263.586 484 323 242 230 315 173 293 104 727 326 184 185
2026/2027204 95 109 0 0 0 0 0 0 0 0 0 0
Totale 10.665